Delivery Order SPE2DB22D2005-SPE2DB26FJDW8
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,744.80 on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL vials (5mL) to support federal medical procurement needs. The award is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 20, 2025, and is funded through the Defense Logistics Agency's Medical Supply Chain division. This contract represents...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency for HYPERRAB 300 Unit/mL vials, with a ceiling value of $1,039.53. The contract is firm fixed price with an ultimate completion date of June 24, 2025, and was awarded on June 2, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a child contract under...
- The Defense Logistics Agency awarded a $3,465.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial, a rabies immunoglobulin product used for post-exposure prophylaxis. The award was issued on May 27, 2025, with an ultimate completion date of June 17, 2025, and represents a non-competitive, non-set-aside procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This delivery...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside competitive award is scheduled for completion by October 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,197.65 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vials, with an ultimate completion date of September 4, 2025. This non-set-aside, competitively awarded contract operates under a firm fixed-price structure and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside, firm fixed-price delivery order carries a ceiling value of $21,489.60 and is scheduled for completion by September 29, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $16,632.48 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $8,954.05 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML, a rabies immunoglobulin product. This firm fixed-price delivery order, issued on August 29, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency issued a delivery order valued at $3,465.10 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This non-set-aside, firm fixed-price delivery order was awarded on July 23, 2025, with an ultimate completion date of August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. HYPERRAB is a rabies immunoglobulin (human) product used for post-exposure prophylaxis and...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB26FJDW8Delivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order valued at $13,860.40 by the Defense Logistics Agency (DLA) for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed-price, non-set-aside contract was executed on October 17, 2025, with an ultimate completion date of November 7, 2025. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. HYPERRAB is a rabies immunoglobulin product used for post-exposure rabies prophylaxis in medical and military healthcare settings. As a prime contractor under the DLA's pharmaceutical supply framework, AmerisourceBergen demonstrates its capability to fulfill federal medical procurement requirements through competitive award processes. The company's extensive contract history with DLA reflects its critical role in supporting military and veteran healthcare systems with a diverse portfolio of pharmaceutical products, vaccines, and specialized medical supplies. This delivery order exemplifies the operational execution of AmerisourceBergen's overarching IDC vehicle, enabling rapid fulfillment of urgent medical supply needs across the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 10/17/25 |